FY2026 EPS Estimates for Oncobiologics Cut by HC Wainwright

Oncobiologics, Inc. (NASDAQ:OTLK) – Stock analysts at HC Wainwright reduced their FY2026 earnings estimates for Oncobiologics in a research note issued on Wednesday, February 18th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.42) for the year, down from their previous estimate of ($0.28). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.21) EPS.

OTLK has been the topic of several other reports. Ascendiant Capital Markets raised their target price on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Wall Street Zen cut Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. Finally, Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Oncobiologics presently has an average rating of “Hold” and an average target price of $6.50.

Oncobiologics Trading Up 6.1%

OTLK stock opened at $0.43 on Friday. The stock has a market capitalization of $36.10 million, a price-to-earnings ratio of -0.17 and a beta of 0.10. The firm’s 50-day moving average price is $0.93 and its two-hundred day moving average price is $1.32. Oncobiologics has a 12-month low of $0.38 and a 12-month high of $3.39.

Oncobiologics (NASDAQ:OTLK) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The company had revenue of ($1.21) million for the quarter, compared to the consensus estimate of $3.14 million.

Institutional Investors Weigh In On Oncobiologics

Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the period. AQR Capital Management LLC lifted its position in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors.

Oncobiologics News Roundup

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital raised its Q4 2026 EPS estimate to ($0.18) from ($0.22), a modest improvement for that quarter which could be seen as a short-term positive for near-term expectations.
• Neutral Sentiment: Chardan Capital reiterated a “Neutral” rating on Oncobiologics, signaling no change in stance from that shop. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating even as it updated earnings models — the reaffirmation removes near-term rating-driven upside but keeps analyst coverage steady. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: A GlobeNewswire release circulating under the OTLK ticker concerns Outlook Therapeutics’ distribution deal in Switzerland — this appears to reference a different company using the same ticker string and may create market confusion; investors should confirm company identity before acting. Outlook Therapeutics Expands European Footprint (GlobeNewswire)
• Negative Sentiment: HC Wainwright trimmed multiple EPS forecasts: Q4 2026 to ($0.05) (from $0.04 previously), FY2026 to ($0.42) (from $0.28) and FY2027 to ($0.21) (from $0.19). These larger-than-expected cuts weigh on forward expectations and valuation.
• Negative Sentiment: Brookline Capital lowered several near-term and FY2026/2027 EPS estimates (e.g., FY2026 to ($0.79) from ($0.74); FY2027 to ($0.20) from ($0.19); quarter-level cuts to Q2/Q3 2026), signaling weaker anticipated performance and adding downside pressure.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.